Author

J. S. McCarthy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

J. A. Simpson· 2 shared A. Kuemmel· 1 shared B. Barber· 1 shared B. E. Barber· 1 shared C. Edwards· 1 shared C. Engwerda· 1 shared D. Andrew· 1 shared D. Corvino· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

J. A. Simpson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Characterisation of Plasmodium vivax lactate dehydrogenase dynamics in P. vivax infections

P. Cao, S. Kho, M. J. Grigg, B. E. Barber, K. A. Piera, T. William, J. R. Poespoprodjo, I. K. Jang, J. A. Simpson, J. McCaw, N. M. Anstey, J. S. McCarthy, S. Britton

This study models PvLDH dynamics in P. vivax infections using Bayesian inference, finding significant differences between ex vivo and in vivo PvLDH levels and half-lives.

bioRxiv · Jun 12, 2023 · PreprintBiophysics

STING activation promotes autologous type I interferon-dependent development of type 1 regulatory T cells during malaria

Y. Wang, F. Rivera, C. Edwards, T. Frame, J. A. Engel, L. Bukali, J. Na, S. Ng, D. Corvino, M. Montes de Oca, P. Bunn, M. Soon, D. Andrew, J. Loughland, F. Amante, , C. Engwerda

This study shows STING activation promotes Tr1 cell development during malaria by enhancing IFNB gene transcription and modulates this pathway with ruxolitinib.

bioRxiv · Sep 4, 2022Immunology

Seeking an optimal dosing regimen for OZ439-DSM265 combination therapy for treating uncomplicated falciparum malaria

S. Dini, S. G. Zaloumis, D. J. Price, N. Gobeau, A. Kuemmel, M. Cherkaoui, J. J. Moehrle, J. S. McCarthy, J. A. Simpson

This study uses a mathematical model to determine an optimal dosing regimen for OZ439-DSM265 combination therapy to treat uncomplicated falciparum malaria, predicting a regimen that cures 90% of patients within 42 days.

bioRxiv · Nov 2, 2020Pharmacology & Toxicology